Global Hepatic Encephalopathy (HE) Therapeutics Market Size By Type (Lactulose, Rifaximin), By Application (Acute Liver Failure, Portal Systemic Bypass Without Liver Disease), By Region, And Segment F...

The Global Hepatic Encephalopathy (HE) Therapeutics Market was valued at USD 1.8 billion in 2023 and is projected to reach USD 3.1 billion by 2031, growing at a CAGR of 6.9% during the forecast period of 2023–2031. Hepatic encephalopathy, a serious neuropsychiatric complication of liver dysfunction, continues to drive significant therapeutic demand due to increasing prevalence of liver cirrhosis, alcohol-related liver disease, and hepatitis infections. Rising awareness, advancements in treatment modalities, and early diagnosis are major factors propelling the market forward.

Drivers:

1. Rising Incidence of Chronic Liver Diseases:

Chronic liver disorders such as cirrhosis and hepatitis B/C significantly contribute to the occurrence of HE. Globally increasing liver-related disease burden is a critical driver for HE therapeutics.

2. Increased Awareness and Early Diagnosis:

Efforts by health organizations to promote liver health and the widespread availability of diagnostic tools are facilitating early detection and management of HE, boosting the demand for therapeutic interventions.

3. Advancements in Therapeutic Options:

Ongoing R&D in HE therapeutics, such as ammonia-lowering agents and gut microbiome modulators, is improving clinical outcomes and expanding treatment options.

Restraints:

1. High Cost of Novel Therapies:

The development and commercialization of advanced HE treatments are associated with high costs, limiting access, especially in low- and middle-income countries.

2. Lack of Awareness in Emerging Economies:

In certain regions, HE remains underdiagnosed due to limited healthcare infrastructure and inadequate medical training, restraining market growth potential.

Opportunity:

1. Expanding Clinical Research Pipelines:

Numerous pharmaceutical companies are investing in clinical trials and drug innovations aimed at targeting the root causes of HE, offering substantial growth prospects.

2. Emerging Markets in Asia-Pacific and Latin America:

The increasing incidence of liver diseases and growing healthcare investments in emerging economies are creating new market opportunities for HE therapeutic providers.

Market by System Type Insights:

Based on system type, lactulose and rifaximin combination therapy remains the largest revenue-generating segment in 2023. This combination is the most prescribed due to its proven efficacy in reducing recurrence rates of HE. However, emerging therapies targeting the gut-brain axis are projected to register the fastest growth rate through 2031, reflecting a shift toward holistic and preventive treatment approaches.

Market by End-use Insights:

Hospitals held the largest market share in 2023 due to the high prevalence of HE among inpatients with advanced liver disease. Hospitals offer comprehensive care, including emergency and critical interventions. The specialty clinics segment is expected to grow significantly, driven by personalized HE management and outpatient follow-ups.

Market by Regional Insights:

North America dominated the market in 2023, driven by a high prevalence of liver disease, supportive reimbursement frameworks, and access to advanced treatments. Meanwhile, Asia-Pacific is anticipated to register the fastest CAGR during the forecast period, fueled by rising healthcare infrastructure, growing awareness, and increasing cases of liver cirrhosis due to lifestyle factors.

Competitive Scenario:

Leading players in the Global Hepatic Encephalopathy Therapeutics Market include:

Salix Pharmaceuticals (a Bausch Health Company)

Mallinckrodt Pharmaceuticals

Umecrine Cognition AB

Kaleido Biosciences

ASKA Pharmaceutical Co., Ltd.

Norgine B.V.

Abbott Laboratories

Ferring Pharmaceuticals

These companies are actively pursuing new drug development, regulatory approvals, and strategic collaborations. For instance:

In 2024, Salix Pharmaceuticals announced new trial results for a next-generation HE therapy targeting the gut-brain axis.

Umecrine Cognition AB received orphan drug status for its novel HE treatment candidate in 2023.

Norgine expanded its distribution network in Asia-Pacific to enhance accessibility to rifaximin-based treatments.

Scope of Work – Global Hepatic Encephalopathy (HE) Therapeutics Market

Key Market Developments:

2023: Salix Pharmaceuticals launched a new campaign to increase awareness and improve adherence to rifaximin therapies.

2024: Kaleido Biosciences initiated a Phase II trial targeting HE via gut microbiome modulation.

2025: ASKA Pharmaceuticals partnered with Japanese hospitals to introduce HE-specific diagnostic tools for early intervention.

FAQs:

1. What is the current market size of the Global Hepatic Encephalopathy (HE) Therapeutics Market?

The market was valued at USD 1.8 billion in 2023.

2. What is the major growth driver of the Global Hepatic Encephalopathy (HE) Therapeutics Market?

The rise in chronic liver disease cases and advancements in treatment options are major growth drivers.

3. Which is the largest region during the forecast period in the Global Hepatic Encephalopathy (HE) Therapeutics Market?

North America holds the largest market share due to advanced healthcare infrastructure and high disease prevalence.

4. Which segment accounted for the largest market share in Global Hepatic Encephalopathy (HE) Therapeutics Market?

The lactulose and rifaximin combination therapy segment led the market in 2023.

5. Who are the key market players in the Global Hepatic Encephalopathy (HE) Therapeutics Market?

Key players include Salix Pharmaceuticals, Mallinckrodt, Norgine, Abbott, and Umecrine Cognition AB.